Introduction
The role of progestins in the pathogenesis of human breast cancer has been highly debated (1) (2) (3) (4) . Although there is convincing evidence that ovarian hormones play a prominent role at all stages of mammary development, epidemiologic studies in general do not support an overall increased risk of breast cancer after progestin treatment. However, oral contraceptives or depot medroxyprogesterone acetate does not decrease the risk of female breast cancer, in contrast to inhibitory effect on the risk of developing endometrial cancer. Furthermore, several epidemiologic studies have linked the use of contraceptive agents during adolescence or before a full-term pregnancy to a higher risk of developing breast cancer at a young age (4-6). The question of whether this increased risk is attributable to the estrogen or the progestin content of the contraceptives has not been answered satisfactorily, but there is good reason to think that this increased risk may be due to the progestin component (7) (8) (9) . This hypothesis is supported by the observations that the highest proliferation rates of mammary epithelium are found in the progesterone-dominated luteal phase of the menstrual cycle and in women receiving progestin-only formulations of contraceptives (3, 10) , indicating a strong mitogenic action of progestins upon mammary epithelium.
In dogs and cats, as in humans, spontaneous forms of benign and malignant mammary gland tumors are found. These animals may therefore provide a model, in addition to the carcinogeninduced mammary tumors in rodents, for the study of comparative aspects of mammary tumor formation. In the dog many toxicity studies have been carried out with estrogens and progestins. Prolonged administration of estrogens does not increase the incidence of mammary tumors in the dog ( 11) , but treatment of female dogs with progestins causes mammary tumor development in a dose-dependent manner (11) (12) (13) (14) (15) . Many of the neoplastic changes are benign, but malignant tumors have also been encountered (14, 15) . Some 14 yr ago it was shown that exogenous (16-18) and endogenous (19) progestins may induce a syndrome of growth hormone (GH)' excess in the dog, leading to acromegalic features and glucose intolerance. The GH excess is reversible upon progestin withdrawal. Very recently we reported that this progestin-induced growth hormone excess originates from foci of hyperplastic ductular epithelium of the mammary gland (20).
In cats progestins also induce mammary hyperplasia, sometimes resulting in extensive fibroadenomatous changes (21). This proliferation of mammary duct epithelium and stroma occurs in the luteal phase of the estrous cycle, in the early stages of pregnancy, and after administration of progestins (22). In cats, however, administration of progestins does not result in increased circulating concentrations of GH (23).
In this study we investigated the sequence of the cDNA encoding mammary GH in the dog and compared this sequence with the cDNA encoding pituitary GH. The presence of the GH mRNA was investigated in normal mammary tissue and in benign and malignant mammary tumors of the dog. The presence of GH mRNA was also investigated in cats with fibroadenomatous changes and other proliferative lesions in the mammary gland.
Methods
Origin of mammary tissue. Eight mammary tissue samples were obtained from female experimental beagle dogs that had been treated with long-acting progestins after ovariohysterectomy. Full . The progestins were administered at 3-wk intervals for a total of 8 injections, stopped for 6 mo, and then resumed at the same doses and intervals for a total of 5 additional injections. Mammary glands were collected immediately after excision, frozen in liquid nitrogen, and stored at -700C until analysis. The other mammary specimens were obtained in the same manner from privately owned dogs and cats that were referred to the Utrecht University Clinic for Companion Animals. Mammary tumors and unaffected mammary tissue were well separated from each other during collection at surgery or, in inoperable cases, at autopsy. Sections from all macroscopically tumorous and nontumorous specimens were processed for routine histopathology and classified as described (24). Reverse transcriptase polymerase chain reaction (RT-PCR). Total RNA was isolated using the guanidinium isothiocyanate (GITC) method. Briefly, 1 g of tissue was homogenized in 10 ml denaturing mix (4 M GITC, 25 mM sodium citrate, 0.5% [wt/vol] sarcosyl, and 1% ,6-mercaptoethanol) by ultra-turrax (Janke & Kunkel, Staufen, Germany) for 30 s. To the homogenate was added 1 ml 2 M NaOAc (pH 4.5), 10 ml phenol, and 2 ml chloroform:iso-amylalcohol (24:1), and this was followed by incubation on ice for 15 min. From the upper phase, obtained after centrifugation for 15 min at 10,000 g, total RNA was precipitated with 10 ml isopropanol by incubation for 1 h at -700C and centrifugation at 3,600 g. The pellet was redissolved in denaturing mix and RNA was again precipitated by isopropanol. After washing with 75% ethanol the RNA pellet was dried under vacuum and redissolved in 10 mM Tris (pH 8.0) containing 1 mM EDTA.
The RNA samples were analyzed by RT-PCR amplification. For the RTs, 1 Og total RNA was added to a 20 Isl (final volume) reaction containing 1 X AMV buffer (Promega Corp., Madison, WI), 5 mM MgCl2, 1 mM of each deoxynucleotide triphosphate, 20 U RNase inhibitor (RNasin; Promega Corp.), 12 U AMV reverse transcriptase, and 2.5 AM Oligo d(T)15 primer. The reaction mixture was overlaid with 50 Al of mineral oil and incubated at 420C for 60 min, followed by heat denaturation at 990C for S min and cooling at 5YC for 5 min. The total RT reaction was then subjected to PCR amplification using cDNA Figure 1 . Size separation by electrophoresis on 1.5% agarose of the RT-PCR products obtained from 1 tig total RNA of canine mammary tissues using porcine specific GH primers. The RT-PCR products were hybridized after a Southern blot using a 32P-labeled canine GH cDNA probe. The codes for the products correspond to the data for the tissue samples in Table I . (A) Samples 1-8 were obtained from female dogs at various stages of the reproductive cycle. Samples 9-16 were obtained after pretreatment with the synthetic progestins MPA or proligeston (Prol). Samples 17-21 were classified as benign mammary tumors. (B) Samples derived from malignant tumors. primers derived from the sequence of the porcine GH gene from the second to the fifth exon (upstream primer: 5 '-TTCCCAGCCATGCCC-TTGTCC; downstream primer: 5 '-CTTGAAGCAGGAGAGCAG-CCC). The upstream primer coincides with the start codon of the GH sequence, which is 60 bp downstream from the start codon of the preprohormone starting with a signal peptide. The downstream primer ends within the coding sequence of the fifth exon. To the RT mixture was added 69.5 Id sterile bidistilled water, 0.5 ul Ampli Taq DNA polymerase (5 U/IA; Promega Corp.), 8 pi 10 x Taq buffer, and 1 p0l of each primer (10 pmol). After an initial denaturation for 5 min at 950C the cDNA was amplified by 35 cycles of 1 min at 950C, 1 min at 550C, and 1 min at 720C. Samples were kept for 10 min at 720C after the last amplification cycle.
10% of the PCR product was size-fractionated by electrophoresis on a 1.5% agarose gel, stained with ethidium bromide, and photographed under ultraviolet light. The PCR products were then transferred by southern blotting to Hybond-N' nitrocellulose membranes (Amersham International, Buckinghamshire, United Kingdom) and hybridized with a 32P-random-labeled canine GH probe purified for sequence analysis.
In an additional study a semi-quantitative RT-PCR was performed for the analysis of the progestin induction of mammary GH mRNA expression. Therefore the RT-PCR of GH mRNA was performed in the presence of primers directed against the mRNA encoding the housekeeping gene /3-actin (upstream primer: 5 '-GGCTGGGGTGTTGAA-GGTCTC; downstream primer: 5 '-GATATCGCCGCGCTCGTCGTC).
Sequence analysis. The 495-bp fragment obtained from mammary tissue of experimental dogs treated with progestins was isolated from the gel and subjected to a second PCR amplification. The sequence of this product was determined by the dideoxy method (25). The 600-bp fragment found in mammary tumor tissue of dogs was also subjected to a second PCR amplification and partially sequenced. The sequences were analyzed with the PCIGENEM' software package (IntelliGenetics, Inc./Betagen, Mountain View, CA). Homology comparisons were made with the EMBL sequence database of the CAOS/CAMM Centre (Nijmegen, The Netherlands).
Immunohistochemistry. The presence of GH in mammary tissue was shown by immunohistochemical analysis of 5-pum sections of frozen specimens of canine mammary tumors as described previously (20). A rabbit anti-porcine GH antiserum was used as the primary antibody. 18  21  <5  26  ND  ND  6  <5  3  <5  42  147  119  40  ND  ND  ND  ND  ND  ND  ND  ND  ND  ND  ND  ND  4  12  2 <3
Samples correspond to the numbers of Fig. 1 (26) .
Results
All experimental dogs treated with high doses of either MPA or proligestone had developed acromegalic features (20). Am-plification of GH mRNA in nontumorous mammary tissue samples of these dogs by RT-PCR using porcine specific GH primers resulted in the presence of a 495-bp fragment in all samples ( Fig. 1 A; Table I ). Single strand conformation polymorphism analysis revealed no difference between the 495-bp products obtained from the pituitary and mammary tissue (not shown). The identity of the mammary and the pituitary products was confirmed by sequence analysis (Fig. 2) . A very high homology was found with pituitary GH sequences of other species. The highest homology was found with mink and porcine GH, and lower homology was found with GH from artiodactyls and from rat and various human GH variant genes (Fig. 3 ). 2030 Mol et al. GH mRNA was expressed in most of the normal, benign, and malignant mammary tissues of dogs, listed in Table I (Fig.  1) . The presence of GH mRNA corresponded to the immunohistochemical staining of tissue specimens with anti-porcine GH antiserum (Fig. 4) . The GH immunoreactivity was predominantly localized in cells of hyperplastic ductular epithelium. Although the RT-PCR is not quantitative, the highest concentrations of the 495-bp fragment were obtained after amplification of cDNA of dogs treated with progestins. GH mRNA was absent in one sample of inactive tissue that was PR negative and in one tissue sample obtained from a dog in anestrus (Table I) . Among the five benign tumors, the lowest amount of GH mRNA was found in a PR-negative tissue sample.
There was a large variation of GH mRNA concentrations in the malignant mammary carcinomas (Fig. 1 B) . The highest levels were found in dogs that had received progestins recently. The expression in primary tumor tissue was higher ( Fig. 1 B, sample 6) or comparable ( Fig. 1 B, sample 7) to that in normal tissue or metastases ( Fig. 1 B, samples 8-10 ) obtained from the same dog. It is noteworthy that GH mRNA expression was found in PR-negative tissue of two solid tumors of dogs that had been ovariohysterectomized at least 3 yr before.
In female cats the highest expression of the 495-bp fragment was found in areas of fibroadenomatous changes induced by the administration of different progestins with or without estradiol (Table II, Fig. 5 ). The expression was also present in mammary tissue of a male cat that had been treated with the synthetic progestin delmadinone acetate (Fig. 5, sample 4) , for its androgen antagonistic properties. No expression was found in two cases of feline epitheliosis. Varying amounts of the 495-bp fragment were present in mammary tissue of cats with mammary carcinomas. The expression was most prominent in a cat receiving megestrol acetate continuously.
For a more quantitative analysis of the GH mRNA expression, the RT-PCR reaction was performed in the presence of primers against GH mRNA and the housekeeping gene ,8-actin ( Fig. 6 ). Ethidium bromide staining of the agarose gels on which the combined PCR products of canine mammary RNA were separated shows an enhanced concentration of the 495-bp GH mRNA product in comparison with the concentration of the 383-bp product of f3-actin after progestin treatment (Fig.   6 ). As shown, a 600-bp fragment is amplified in the RT-PCR. In other tissue samples, whether normal, hyperplastic, or neoplastic, a 600-bp fragment was also amplified. This fragment did not react with the canine GH probe on the Southern blot, indicating that this fragment was not related to the GH mRNA. Sequence analysis of the 600-bp fragment failed to demonstrate an unambiguous homology to well-known genes of other species. Translation of the 5' side of the PCR product, using an open reading frame, showed motifs in the corresponding protein sequence of a glycosaminoglycan attachment site and an RGD structure pointing to a cell attachment sequence (Fig. 7 ).
Discussion
The demonstration of the expression of the gene encoding pituitary GH in canine and feline mammary tumors reveals a new aspect of the local endocrine environment of normal and tumorous mammary epithelium. In the past decade, investigation of mechanisms involved in the growth regulation of breast cancer has changed from the concept of systemic endocrine stimulation of proliferation towards autocrine and paracrine processes. In the growth regulation of breast cancer cells, peptidergic growth factors play a prominent role. cDNA probes have revealed the expression of TGFa, IGF-II, and PDGF in breast cancer epithelial cells (27).
In research on endocrine stimulation of breast cancer the main attention has been focused on estrogens and prolactin, which are also produced in the mammary gland (28, 29). It has been shown that in human breast cancer there is autonomous regulation of the tissue estradiol concentration (29) , which does not depend on plasma levels. The primary role of estrogens may be mainly related to induction of the PR concentration (10) . In the dog, prolonged treatment with estrogens does not increase the incidence of mammary tumors ( 11) and is also not a prerequisite for the induction of GH excess by progestins (18, 20) . In our limited series of feline fibroadenomatous lesions, expression of GH mRNA was found in animals treated with progestins and appeared not to depend on treatment with estrogens. GH mRNA expression was even present in a male cat treated with a synthetic progestin.
Of the pituitary hormones both nonlactogenic and lactogenic forms of GH have been proved to be far more potent than prolactin in directly stimulating mammary gland differentiation (31 ) . Malignant transformation may occur during the recruitment phase, giving rise to mammary cancer originating from mammary stem cells in both humans (32) and dogs (33) . Moreover, progestins may enhance the mammary production of IGF-11, as shown in the human breast cancer cell line T-47D (34). Taken together, the progestin-induced synthesis and release of GH and of IGF-11 may generate an environment highly promoting proliferation of the mammary epithelium. In humans, administration of high doses of MPA The bar represents 15 jtm. increases plasma IGF-I levels (35) , most probably via increased plasma GH levels. Whether this is caused by local mammary GH production needs to be clarified. In view of the finding of progestin-induced GH expression in the mammary gland and the well-known tumor-promoting effect of progestins in dogs and cats ( 11) , additional studies are needed to determine whether the tumorigenic effect of the steroid hormones is mediated by GH and GH-stimulated growth factors.
Progestins may temporarily enhance sensitivity to carcinogens by creating a highly proliferative environment. It is uncertain whether GH induction in the mammary gland is involved in this proliferative effect and contributes to tumorigenesis, or whether instead the local GH effects promote differentiation of the gland and are thus protective against initiation of tumor development.
In the benign mammary tumors of dogs and cats, a definite relationship was found between the presence of GH mRNA and exposure to endogenous or exogenous progestins. Such a 2032 Mol et al. relation was much less certain for the malignant mammary tumors. It cannot be excluded that in some of the latter tumors GH is produced constitutively even by PR-negative cells. Studies are needed to relate GH production to steroid receptor concentrations and biologic behavior of the tumor. The expression of the 600-bp fragment was not related to GH mRNA expression or to histologic criteria of malignancy. The presence of a glycosaminoglycan attachment site and an RGD sequence suggests that this protein belongs to the family of proteoglycans. These proteins are important modifiers of the organization of the pericellular and extracellular matrices. Their functions range from linking proteins to hyaluronan to providing a binding site for fibroblast growth factor or TGF/3 in the extracellular matrix (36, 37) . The function of this canine protein in cell attachment and/or metastasis needs further characterization.
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These data indicate that progestins stimulate benign proliferation of mammary tissue in the dog and the cat by the local induction of the GH gene. In the dog this results in acromegalic features due to high plasma levels of GH and IGF-I (20). Elevated plasma IGF-I levels may act in concert with the mam- 
